Vaccentis is pleased to announce that Matt Regan and Dr Seng Chin Mah have recently joined our Board of Directors.
Their extensive expertise in healthcare and the industry will contribute to Vaccentis’ mission of accelerating the development of the precision cancer immunotherapy VCC-001, thus opening a new chapter in individualized medicine.
This move strengthens our Board of Directors even further and marks another important milestone in our company's history, following the opening of our EU hub in Vienna this autumn and the appointment of Patrik Grandits to our Board this summer.
We warmly welcome Mr Regan and Dr Mah and look forward to shaping the next phase of Vaccentis' growth together!
Link to press release: https://www.brandensteincom.at/vaccentis-expands-its-board-of-directors-with-additional-healthcare-experts/
